ANAB Stock — AnaptysBio Inc.: Cash, EV, Pipeline

Share price

$55.20

Market cap

$1,634.4M

Cash

$286.5M

Enterprise value

$1,347.9M

Balance sheet

Cash	$286.5M
Debt	$0.0M
Net cash	$286.5M
Enterprise value	$1,347.9M
Basic shares	29.0M shares
Fully diluted shares	39.6M shares
Fully diluted market cap	$2,183.9M
Cash per share	$9.88

Cash figures as of 2026-03-31. Database snapshot: 2026-09-21.

Price history

Loading ANAB daily closes…

Loading price history…

Pipeline assets

Jemperli

Approved · Active Modality: antibody

Aliases dostarlimab

Target PD-1

Partnerships GSK (TESARO): collaboration & exclusive license (2014); tiered royalties + milestones; Jemperli royalties partially monetized to Sagard

Indications

Endometrial cancer (dMMR/MSI-H) (Approved)
Pan-deficient mismatch repair tumors (Approved)

Status note Royalty interest only; developed and marketed by GSK (FDA approved Apr 2021, full approval Feb 2023; chemo combo approved Jul 2023 and Aug 2024; EMA 2021/2025). Retained by ANAB post-separation; separation completed April 20, 2026.

Imsidolimab

Phase 3 · Active Modality: monoclonal antibody

Target IL-36R

Partnerships Vanda: exclusive global license (Jan 2025); royalty/milestone-bearing; milestone rights allocated to First Tracks per separation agreement

Indications

Generalized pustular psoriasis (GPP) (Phase 3)

Catalysts

— December 12, 2026

Status note IL-36R antagonist mAb. Two registration-enabling global Phase 3 trials (GEMINI-1, GEMINI-2) completed; BLA submitted Dec 2025, accepted Feb 2026. Royalty interest retained by ANAB; Vanda develops/commercializes. Separation completed April 20, 2026.

Per-asset detail extracted from the 10-Q filed 2026-05-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Rosnilimab
Lead indication	Rheumatoid Arthritis
Lead phase	Phase 2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06041269	Phase 2	Active, not recruiting	Sponsor	ANAB	—	Rheumatoid Arthritis	—
NCT06127043	Phase 2	Active, not recruiting	Sponsor	ANAB	—	Ulcerative Colitis	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for AnaptysBio, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	3,698	no change	0.01%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

ANAB — AnaptysBio Inc.